American Health Intel Rules. Money. Medicine. Decoded daily.
Subscribe
The Regulator · Tuesday, November 17, 2026

The Regulator

Rules. Money. Medicine. Decoded daily.
5 stories · 4 min read
Reading as

FDA proposed a rule that would make N-acetyl-L-cysteine (NAC) a lawful dietary supplement ingredient, and puts the cost of the change at $848 in total. The Food and Drug Administration (FDA) published the proposal in today’s Federal Register. NAC is also sold as an FDA-approved drug, and federal law excludes an ingredient from the dietary supplement definition when it was approved as a drug before it was marketed as a supplement. FDA says it currently exercises enforcement discretion on certain NAC products labeled as supplements, so this rule would replace discretion with a written rule. The agency would create a new regulation, 21 CFR 190.1, with NAC as its first listed ingredient, and says this is the first time it has used its authority to clear an otherwise excluded ingredient. Who it hits: supplement makers and sellers, who would get legal certainty, and drug makers with NAC products, who would share the shelf. FDA says few firms operate in the NAC market, so its estimated cost is about $99 a year, and $848 in present value, mostly the cost of reading the rule, and it does not estimate benefits. Comments are due January 19, 2027 under docket FDA-2025-N-2699. Confidence: High on the proposal’s terms, which come from the notice itself. Sources: Federal Register proposed rule, 91 FR 73717.

NIH proposes to drop the independent safety board requirement for all phase 3 and multi-site trials it funds. The National Institutes of Health (NIH) published a draft update to its 1998 Policy for Data and Safety Monitoring as a request for information in today’s Federal Register. The draft would widen the policy from clinical trials to all NIH-supported clinical research, require a monitoring plan scaled to each study’s risk, and have NIH institutes approve those plans. It would remove the requirement for a Data and Safety Monitoring Board, an independent panel that reviews trial safety data, on every phase 3 or multi-site trial. NIH says almost two thirds of its clinical research portfolio is not clinical trials, and that the change would cut administrative burden on lower-risk studies. Who it hits: university investigators, research compliance offices and the contract research firms that staff monitoring boards, though NIH gives no dollar figure in the notice. Comments are due January 6, 2027. Confidence: High on the draft’s terms; Low on how many studies would lose a board, which the notice does not quantify. Sources: Federal Register request for information, 91 FR 73764.

The Senate health committee votes Wednesday on Heidi Overton’s nomination to lead the FDA. The Senate Health, Education, Labor and Pensions (HELP) Committee lists an executive session for November 18 at 9:45 a.m. covering five nominees, including Overton for Commissioner of Food and Drugs. A favorable vote sends her to the full Senate. Per Politico as relayed by the trade outlet RAPS, several Republican senators, including outgoing chair Bill Cassidy, had not said whether they would support her, and acting commissioner Kyle Diamantas is expected to leave at year end. The Senate calendar page does not state vote counts, and we could not confirm those reports at the primary level. Who it hits: every drug and device sponsor with an application at FDA, since the agency has been under acting leadership. Confidence: High on the scheduled vote; Low on whip counts. Sources: Senate HELP Committee executive session page. Supplemental: RAPS This Week at FDA, November 13.

UPDATE on the U.S. measles status story we covered November 16: the Pan American Health Organization has still not posted its finding. PAHO’s news page listed no measles statement when we checked. Al Jazeera reported November 12 that PAHO’s Regional Monitoring and Re-Verification Commission began meeting November 10 and was due to finish Friday, then pass recommendations to PAHO Director Jarbas Barbosa, who makes the final call, with an announcement expected early this week. Al Jazeera also quotes CDC Director Erica Schwartz telling Reuters that losing the status would not change the agency’s approach. Who it hits: state and local health departments running outbreak response. The KFF Health News report of a lost status still rests on unnamed sources. Confidence: Low on the outcome; High that no PAHO document was posted at the time we checked. Sources: PAHO news page. Supplemental: Al Jazeera explainer, KFF Health News report.

FDA ruled that the brand multivitamin injections M.V.I. Adult and M.V.I. Pediatric were not withdrawn for safety or effectiveness reasons. Two Federal Register notices today carry the determinations. They let FDA approve abbreviated new drug applications, the shortcut filing for generic copies, for the two products’ formulations, provided other legal and regulatory requirements are met. Who it hits: generic injectable makers weighing a filing, and hospital pharmacies that buy intravenous vitamins. The notice summaries give no market-size figure or approval timeline, so any savings are unquantified. Confidence: High on the determinations. Sources: Federal Register notice, M.V.I. Adult, 91 FR 73758, Federal Register notice, M.V.I. Pediatric, 91 FR 73759.

Quiet note: the Federal Register’s other health filings today were meeting notices, information-collection notices and an NIH reorganization notice, and we found no new CMS rule or notice.

Get tomorrow's edition in your inbox.

Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.

Where these stories are tracked
Get the next issue Free, daily